search
Back to results

Stroke Feasibility Study

Primary Purpose

Atrial Fibrillation, AFib

Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AtriClip LAA Exclusion Device
Sponsored by
AtriCure, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring Left Atrial Appendage, LAA, Atrial Fibrillation, AFib, AF, IRB approved, clinical, Stroke, TIA, contraindication to oral anticoagulation therapy, Arrhythmias, Cardiac, OAC, trial, study, LAA occlusion, occluded, prevent

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is ≥ 18 years and ≤ 80 years of age.
  2. Patient has electrocardiographically confirmed non-valvular atrial fibrillation (paroxysmal, persistent, or longstanding persistent AF).
  3. CHADS2 or CHA2DS2VASc score ≥2.
  4. Patient has medical contraindication to long term anticoagulant therapy (OAC), defined as one or more of the following:

    • history of intracranial bleeding (e.g. due to amyloid angiopathy or other condition) which renders patient unsafe for OAC;
    • history of gastrointestinal, genitourinary, or respiratory tract bleeding due to permanent condition which renders patient unsafe for OAC;
    • HAS-BLED Score ≥ 3.
  5. Patient is considered an acceptable surgical candidate, including use of general anesthesia.
  6. Female patients must be of non-child bearing potential, or have a negative pregnancy test within 7 days prior to index procedure.

Exclusion Criteria:

  1. Stroke within 30 days, or TIA within 3 days, respectively, prior to index procedure.
  2. Documented medical history of any penetrating trauma to thorax, or blunt trauma to thorax which resulted in a left pneumothorax or left hemothorax.
  3. Myocardial infarction within 60 days prior to index procedure.
  4. NYHA Class IV heart failure.
  5. Ejection fraction < 40% (based on baseline transthoracic echocardiography (TTE)).
  6. Prior attempted obliteration of left atrial appendage (percutaneous or open cardiac surgery).
  7. Previous catheter ablation with perforation or complication.
  8. Prior open cardiac surgery, or percutaneous coronary intervention with associated unintended cardiac perforation, or pericardial adhesions are suspected.
  9. History of pericarditis or pericardiocentesis.
  10. Active infection, septicemia, or fever of unknown origin.
  11. Concomitant elective surgical procedure (in addition to AtriClip placement) at the time of index procedure.
  12. Planned atrial arrhythmia ablation procedure within six months following index procedure.
  13. Underlying structural heart disease requiring planned surgical treatment within six months following the index procedure.
  14. Cardiac or thoracic surgical procedure within the thirty days prior to index procedure.
  15. Anticoagulation therapy for other medical condition (i.e. deep vein thrombosis) is required.
  16. Patient unable to discontinue thienopyridines (e.g. clopidogrel) or non-ASA antiplatelet agents 4 days pre-operatively and abstain for at least 2 days post-operatively.
  17. Renal Failure as defined by creatinine > 2.0 mg/dl (> 152.5 umol/L) and/or need for dialysis.
  18. Known carotid artery diameter stenosis greater than 80%.
  19. Patient has symptomatic or high-grade carotid disease (>70% bilaterally).
  20. Patient unable or unwilling to undergo transesophageal echocardiography (TEE).
  21. Presence of thrombus in the left atrium or LAA, as determined by baseline TTE or Computed Tomography Angiogram (CTA).
  22. Documented history of thrombophilic disorder, with diagnosis established via previous objective testing (e.g. familial screening for thrombophilia).
  23. Moderate to Severe Chronic Obstructive Pulmonary Disease (FEV1 or VC<70% predicted) or intolerant of single lung ventilation.
  24. History of Hypercoagulopathy
  25. Body Mass Index (BMI) > 35.
  26. Other medical illness or comorbidity that may cause non-compliance with the protocol, confound data interpretation (e.g. severe dementia), or limited life expectancy (i.e. < 3 months).
  27. Enrolled in another investigational device or drug study at the time of enrollment and during the course of the study.
  28. Psychiatric disorder which in the judgment of the investigator could interfere with informed consent, completion of tests, therapy, or follow-up.
  29. Patient is pregnant or intends to become pregnant within 6 months post-index procedure.

Intraoperative Exclusion Criteria

  1. Left atrial appendage width < 29mm or > 50mm, based on TEE imaging.
  2. Presence of thrombus in the left atrium or LAA based on TEE imaging.

Sites / Locations

  • St. Helena Hospital
  • Mercy Hospital
  • Franciscan St. Francis Health
  • Good Samaritan Hospital
  • Houston Methodist Hospital
  • University of Virginia
  • Aspirus

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

AtriClip LAA Exclusion Device

Arm Description

AtriClip delivered via minimally invasive surgical procedure

Outcomes

Primary Outcome Measures

Number of Serious Adverse Events Within 30 Days Post-Index Procedure
The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator: Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke Major bleeding (defined as requiring re-operation and/or transfusion (> 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).
Composite Left Atrial Appendage Placement and Exclusion Success
Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following: Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient. Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and <10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE. 3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and < 10mm residual pocket) between the LA and LAA at >=3 month TEE or CTA evaluation.

Secondary Outcome Measures

Rate of Stroke and Non-CNS Systemic Embolism
The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure: Stroke (ischemic ) Non-CNS (Central Nervous System) systemic embolism.
Serious Device or Procedure Related Adverse Event Rate
Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator.
Overall Serious Adverse Event Rate
Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.
Overall Adverse Event Rate
Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.

Full Information

First Posted
November 21, 2013
Last Updated
October 27, 2016
Sponsor
AtriCure, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT01997905
Brief Title
Stroke Feasibility Study
Official Title
Feasibility Clinical Investigation of a Minimally Invasive Surgically Deployed AtriCure AtriClip Left Atrial Appendage Exclusion System for Stroke Prophylaxis in Patients With Non-Valvular Atrial Fibrillation and in Whom Long Term Oral Anticoagulation Therapy is Medically Contraindicated
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
August 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AtriCure, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage. The purpose is for evaluation of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation who are unable to take Oral Anticoagulants.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation, AFib
Keywords
Left Atrial Appendage, LAA, Atrial Fibrillation, AFib, AF, IRB approved, clinical, Stroke, TIA, contraindication to oral anticoagulation therapy, Arrhythmias, Cardiac, OAC, trial, study, LAA occlusion, occluded, prevent

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
13 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AtriClip LAA Exclusion Device
Arm Type
Experimental
Arm Description
AtriClip delivered via minimally invasive surgical procedure
Intervention Type
Device
Intervention Name(s)
AtriClip LAA Exclusion Device
Other Intervention Name(s)
LAAØ, PRO1, AtriClip™ LAA Exclusion System, AtriClip™ LAA Exclusion System w/ preloaded Gillinov-Cosgrove™ Clip, AtriClip LAA Exclusion System and Delivery System (LAAØ), AtriClip LAA Exclusion System and Delivery System (PRO1)
Primary Outcome Measure Information:
Title
Number of Serious Adverse Events Within 30 Days Post-Index Procedure
Description
The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator: Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke Major bleeding (defined as requiring re-operation and/or transfusion (> 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).
Time Frame
30 days post-index procedure
Title
Composite Left Atrial Appendage Placement and Exclusion Success
Description
Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following: Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient. Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and <10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE. 3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (<3 mm residual communication with LAA and < 10mm residual pocket) between the LA and LAA at >=3 month TEE or CTA evaluation.
Time Frame
Immediate to 3-months post-index procedure
Secondary Outcome Measure Information:
Title
Rate of Stroke and Non-CNS Systemic Embolism
Description
The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure: Stroke (ischemic ) Non-CNS (Central Nervous System) systemic embolism.
Time Frame
3 months and 6 months post-index procedure
Title
Serious Device or Procedure Related Adverse Event Rate
Description
Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator.
Time Frame
3 month and 6 month post-index procedure
Title
Overall Serious Adverse Event Rate
Description
Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.
Time Frame
3 month and 6 month Post Index Procedure
Title
Overall Adverse Event Rate
Description
Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.
Time Frame
3 month and 6 month post-index procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is ≥ 18 years and ≤ 80 years of age. Patient has electrocardiographically confirmed non-valvular atrial fibrillation (paroxysmal, persistent, or longstanding persistent AF). CHADS2 or CHA2DS2VASc score ≥2. Patient has medical contraindication to long term anticoagulant therapy (OAC), defined as one or more of the following: history of intracranial bleeding (e.g. due to amyloid angiopathy or other condition) which renders patient unsafe for OAC; history of gastrointestinal, genitourinary, or respiratory tract bleeding due to permanent condition which renders patient unsafe for OAC; HAS-BLED Score ≥ 3. Patient is considered an acceptable surgical candidate, including use of general anesthesia. Female patients must be of non-child bearing potential, or have a negative pregnancy test within 7 days prior to index procedure. Exclusion Criteria: Stroke within 30 days, or TIA within 3 days, respectively, prior to index procedure. Documented medical history of any penetrating trauma to thorax, or blunt trauma to thorax which resulted in a left pneumothorax or left hemothorax. Myocardial infarction within 60 days prior to index procedure. NYHA Class IV heart failure. Ejection fraction < 40% (based on baseline transthoracic echocardiography (TTE)). Prior attempted obliteration of left atrial appendage (percutaneous or open cardiac surgery). Previous catheter ablation with perforation or complication. Prior open cardiac surgery, or percutaneous coronary intervention with associated unintended cardiac perforation, or pericardial adhesions are suspected. History of pericarditis or pericardiocentesis. Active infection, septicemia, or fever of unknown origin. Concomitant elective surgical procedure (in addition to AtriClip placement) at the time of index procedure. Planned atrial arrhythmia ablation procedure within six months following index procedure. Underlying structural heart disease requiring planned surgical treatment within six months following the index procedure. Cardiac or thoracic surgical procedure within the thirty days prior to index procedure. Anticoagulation therapy for other medical condition (i.e. deep vein thrombosis) is required. Patient unable to discontinue thienopyridines (e.g. clopidogrel) or non-ASA antiplatelet agents 4 days pre-operatively and abstain for at least 2 days post-operatively. Renal Failure as defined by creatinine > 2.0 mg/dl (> 152.5 umol/L) and/or need for dialysis. Known carotid artery diameter stenosis greater than 80%. Patient has symptomatic or high-grade carotid disease (>70% bilaterally). Patient unable or unwilling to undergo transesophageal echocardiography (TEE). Presence of thrombus in the left atrium or LAA, as determined by baseline TTE or Computed Tomography Angiogram (CTA). Documented history of thrombophilic disorder, with diagnosis established via previous objective testing (e.g. familial screening for thrombophilia). Moderate to Severe Chronic Obstructive Pulmonary Disease (FEV1 or VC<70% predicted) or intolerant of single lung ventilation. History of Hypercoagulopathy Body Mass Index (BMI) > 35. Other medical illness or comorbidity that may cause non-compliance with the protocol, confound data interpretation (e.g. severe dementia), or limited life expectancy (i.e. < 3 months). Enrolled in another investigational device or drug study at the time of enrollment and during the course of the study. Psychiatric disorder which in the judgment of the investigator could interfere with informed consent, completion of tests, therapy, or follow-up. Patient is pregnant or intends to become pregnant within 6 months post-index procedure. Intraoperative Exclusion Criteria Left atrial appendage width < 29mm or > 50mm, based on TEE imaging. Presence of thrombus in the left atrium or LAA based on TEE imaging.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Basel Ramlawi, MD
Organizational Affiliation
Methodist Hospital Houston
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Helena Hospital
City
St. Helena
State/Province
California
ZIP/Postal Code
94574
Country
United States
Facility Name
Mercy Hospital
City
Miami
State/Province
Florida
ZIP/Postal Code
33133
Country
United States
Facility Name
Franciscan St. Francis Health
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46237
Country
United States
Facility Name
Good Samaritan Hospital
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45220
Country
United States
Facility Name
Houston Methodist Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Virginia
City
Charlottesville
State/Province
Virginia
ZIP/Postal Code
22908
Country
United States
Facility Name
Aspirus
City
Wausau
State/Province
Wisconsin
ZIP/Postal Code
54401
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Stroke Feasibility Study

We'll reach out to this number within 24 hrs